6055 A randomized phase II study of Xeloda with or without oxaliplatin as a first-line treatment in the elderly patients with metastatic colorectal cancer: Korean Cancer Study Group

Y.S.Hong; S.Y.Kim; K.H.Jung; J.L.Lee; Y.S.Park; J.B.Ahn; J.H.Kim; B.Y.Shim; D.Y.Zang; T.W.Kim

首页> 外文期刊>European Journal of Cancer Supplements >6055 A randomized phase II study of Xeloda with or without oxaliplatin as a first-line treatment in the elderly patients with metastatic colorectal cancer: Korean Cancer Study Group

【24h】

6055 A randomized phase II study of Xeloda with or without oxaliplatin as a first-line treatment in the elderly patients with metastatic colorectal cancer: Korean Cancer Study Group

机译：6055韩国老年癌症研究小组对西洛达联合或不联合奥沙利铂作为老年转移性结直肠癌患者一线治疗的随机II期研究：

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European Journal of Cancer Supplements》 |2009年第2期|共1页
作者
Y.S.Hong; S.Y.Kim; K.H.Jung; J.L.Lee; Y.S.Park; J.B.Ahn; J.H.Kim; B.Y.Shim; D.Y.Zang; T.W.Kim;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Randomized phase II study of capecitabine with or without oxaliplatin as first-line treatment for elderly or fragile patients with metastatic colorectal cancer : A prospective, multicenter trial of the Korean cancer study group CO06-01 [J] . HongY.S., JungK.H., KimH.J., American Journal of Clinical Oncology: Cancer Clinical Trials . 2013,第6期

机译：卡培他滨联合或不联合奥沙利铂作为老年或脆弱转移性结直肠癌一线治疗的随机II期研究：韩国癌症研究组CO06-01的一项前瞻性，多中心试验
2. Randomized, Phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) Versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study [J] . DouillardJ.-Y., SienaS., CassidyJ., Journal of Clinical Oncology . 2010,第31期

机译：帕尼单抗与氟尿嘧啶，亚叶酸和奥沙利铂（FOLFOX4）输注的随机，III期试验与单独使用FOLFOX4作为先前未经治疗的转移性结直肠癌患者的一线治疗：PRIME研究
3. 627 POSTER UFT/LV combined with oxaliplatin (TEGAFOX) or with irinotecan (TEGAFIRI) as first-line treatment for metastatic colorectal cancer patients (pts). results of a randomized phase II I.T.M.O. study [J] . European Journal of Cancer Supplements . 2005,第2期

机译：627 POSTER UFT / LV联合奥沙利铂（TEGAFOX）或伊立替康（TEGAFIRI）作为转移性结直肠癌患者（pts）的一线治疗。 I.T.M.O随机第二阶段的结果研究
4. Prospective Randomized Clinical Study on the Necessity of Chemical Cleaning in Patients with Colorectal Cancer [C] . T. Hone, M. Ishizuka, K. Takagi, Asian Federation of Coloproctology . 2005

机译：直肠癌患者化学清洁必要性的预期随机临床研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Rationale and design of the TRUSTY study: a randomised multicentre open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy [O] . Takayuki Yoshino, Eiji Oki, Hiroaki Nozawa, 2018

机译：TRUSTY研究的原理和设计：三氟哌啶/替匹西酯加贝伐单抗与伊立替康氟嘧啶+贝伐单抗作为二线治疗的转移性结直肠癌患者在第一期或之后进展的随机多中心II / III期开放性研究基于奥沙利铂的化疗
7. S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study [O] . Hideo Baba, Yasuhide Yamada, Daisuke Takahari, 2017

机译：S-1和Oxaliplatin（Sox）加贝伐单抗与Mfolfox6加上贝伐单抗作为转移性结肠直肠癌患者的一线治疗：更新了开放标签，非劣势，随机阶段III：软化研究的整体存活分析

6055 A randomized phase II study of Xeloda with or without oxaliplatin as a first-line treatment in the elderly patients with metastatic colorectal cancer: Korean Cancer Study Group

著录项

相似文献

相关主题

期刊订阅